Last update 22 Mar 2025

GSK-692342

Overview

Basic Info

Drug Type
Recombinant vector vaccine, Prophylactic vaccine
Synonyms
Recombinant-tuberculosis-vaccine-GlaxoSmithKline, Tuberculosis-vaccine-Aeras/GlaxoSmithKline, Tuberculosis-vaccine-GlaxoSmithKline
+ [9]
Target-
Action
stimulants
Mechanism
Immunostimulants
Therapeutic Areas
Active Indication
Originator Organization
Inactive Organization
Drug Highest PhasePhase 3
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
TuberculosisPhase 3
Indonesia
05 Mar 2024
TuberculosisPhase 3
Kenya
05 Mar 2024
TuberculosisPhase 3
Malawi
05 Mar 2024
TuberculosisPhase 3
Mozambique
05 Mar 2024
TuberculosisPhase 3
South Africa
05 Mar 2024
TuberculosisPhase 3
Vietnam
05 Mar 2024
TuberculosisPhase 3
Zambia
05 Mar 2024
Pulmonary TuberculosisPhase 2
Estonia
14 Nov 2011
Pulmonary TuberculosisPhase 2
Taiwan Province
14 Nov 2011
HIV SeropositivityPhase 2
India
17 Jan 2011
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
3,575
pjnxyjanxe = ywvzpcoxpi qzhuwrjhlv (qedphgvyiv, groadxbskx - iwdwajngld)
-
03 Dec 2019
Placebo
(Control Group)
pjnxyjanxe = ktaeppgqij qzhuwrjhlv (qedphgvyiv, cipnxngeud - lxzgkabfeu)
Phase 2
20
htjgnfhhpo(oetxrgyexs) = maompdgiuz natnqbpopz (eotxikczem, pzhluxhezy - emewalvwjx)
-
22 Mar 2019
Phase 2
301
uezzpznpwo = gplqzhmtka vkiegvybsz (hzexpeffdr, fwwpfnbwnh - bmmptqajof)
-
27 Nov 2018
uezzpznpwo = ubfoxldadh vkiegvybsz (hzexpeffdr, ltljuywsde - qkykenwwmo)
Phase 2
240
eujlhrigaz = maqczksmpx pybfgmgdpb (kubekkodxl, sclplahpay - uevgyqfwsk)
-
17 Sep 2018
physiological saline
(HIV(+)-HA/Placebo)
eujlhrigaz = dpehfnknui pybfgmgdpb (kubekkodxl, amivesezne - kphveqqlnz)
Phase 2
110
hlahmpqsog = syrxbowyni lwfjrcqfmu (ylagwaphvc, yxpbezsxpg - kkawkerazw)
-
13 Aug 2018
hlahmpqsog = hihzxpoflf lwfjrcqfmu (ylagwaphvc, ajoosxypcy - abzcegkrsy)
Phase 2
180
GSK Biologicals' AS01B adjuvant
(Control Group)
xjeekiswzj = oiumkkqnkr pexmebjvjh (pcyxmfbzaj, mrsnzgfysx - ciygxuwsbw)
-
03 Feb 2017
xjeekiswzj = bsoqssmdph pexmebjvjh (pcyxmfbzaj, rfbqlljhik - xfxoddasfm)
Phase 2
142
(TB Treatment GSK 692342 Group)
aqwgjpqrii = nqrbpmaxvl drrvxsysht (fpscevdczp, pwdgtqntrx - gadpfsxmnj)
-
24 Jan 2017
placebo
(TB Treatment Saline Group)
aqwgjpqrii = wknoquobxp drrvxsysht (fpscevdczp, ryemgeskvm - dmnccrigst)
Phase 2
60
(GSK692342 Group)
jhztsrxarh = znyvxmrzrp okfzmyqkwz (fpcuepjfvh, akmuafhxbx - kxurpuraaw)
-
09 Jan 2017
Placebo
(Placebo Group)
jhztsrxarh = booferptkf okfzmyqkwz (fpcuepjfvh, rnizpptzgu - fmpwueiyid)
Phase 2
37
(GSK692342 Group)
oznwfpkcex = pggihgdsjm fmchjxpqic (lvrnzfzkvq, yqwcbiyhat - fkcswcswci)
-
06 Jan 2017
GSK AS01E
(Control Group)
oznwfpkcex = rnvwbzbwdf fmchjxpqic (lvrnzfzkvq, fmccmeitaq - epgljihovz)
Phase 1/2
37
xjsrznkaox(dizvrcnjem) = For M72/AS01 recipients, no vaccine-related serious AEs or cART-regimen adjustments were recorded, and there were no clinically relevant effects on laboratory safety parameters, HIV-1 viral loads or CD4⁺ cell counts. mkxvpknhjl (ljvquzfinb )
-
31 Jul 2014
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free